Crisnatol is a derivative of arylmethylaminopropanediol with significant antineoplastic activity in a variety of murine and human tumor models. Crisnatol functions as a DNA intercalator, with the presence of additional basic amine groups in the sidechain enhancing binding to DNA due to electrostatic interactions. Crisnatol did not show antitumor efficacy in patients with ovarian carcinoma. In another clinical study, 2 of 26 patients with glioma showed complete long-lasting responses to the drug. The dose-limiting side effect was neurotoxicity.

Losulazine (U-54,669F) is an antihypertensive agent acting by a sympatholytic mechanism. It appears to alter peripheral sympathetic neurogenic function but apparently does not enter the central nervous system. Losulazine effectively lowered the blood pressure in patients with hypertension.

Methaphenilene, an antihistaminic agent, was studied as a peroxisome proliferator. Information about the current use of this compound is not available.

Taclamine is an isoquinoline derivative patented by Ayerst, McKenna and Harrison Ltd. as central nervous system depressant and anti-inflammatory agent. In preclinical models, Taclamine antagonizes the turnover of noradrenaline and dopamine in the rat brain during immobilization stress without effects on brain serotonin turnover

Dexsecoverine ia an antimuscarinic drug.

Ditiocarb, the sodium salt of diethyldithiocarbamate, is a drug with strong antioxidant capacity and chelating activities. It improves the depressed immune responses of newborn and aged mice and mice that are treated with chemotherapy or irradiation. Ditiocarb prevents cisplatin nephrotoxicity in animals without reducing the drug's antitumor activity. Ditiocarb has therapeutic activity in the LP-BM5 murine retrovirus-induced immunodeficiency disease. In that AIDS model, it reduces lymphadenopathy and hypergammaglobulinemia, restores immunocompetence, and prolongs survival. Ditiocarb was safe and reduced the incidence of opportunistic infections in patients with symptomatic HIV infection but ditiocarb had no positive effect on HIV patients. The administration of ditiocarb did not induce any major adverse clinical or biological reactions. Sixty-four patients with nonmetastatic high-risk breast cancer were randomized in a double-blind trial of adjuvant immunotherapy with sodium ditiocarb (DDC) versus placebo. At 6 years, overall survival was 81% in DDC group versus 55%.

Amiquinsin hydrochloride, 4-amino-6,7-dimethoxquinoline hydrochloride hydrate, is a drug, which exhibits hypotensive activity. Amiquinsin has a more prolonged hypotensive effect than the hydroxyquinoline.

MK-212 is a 5HT2C-receptor agonist. It displays selectivity for 5-HT2C over 5-HT2A (IC50 values are 0.028 and 0.42 uM for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively). A dose-dependent the effect of 5HT2C-receptor agonist MK-212 on mouse behavior was demonstrated. Intraperitoneal injection of MK-212 in high doses (0.5 and 1.0 mg/kg) increased blood level of corticosterone in mice and reduced their motor activity. In low doses of 0.1 and 0.2 mg/kg, the agonist reduced anxiety, but had no effect on motor activity. It is hypothesized that low doses of MK-212 exhibited anxiolytic activity in mice.

Ampyzine is a pyrazine derivative patented by Warner-Lambert Pharmaceutical Co. as a central nervous system stimulant.

Triampyzine is an anticholinergic, antisecretory agent.